MGC Pharmaceuticals Ltd (ASX: MXC) wants to be an innovator in the global Phytocannabinoid-based medicine. It has technical and professional experience of several years. The company wants to create and supply high-quality Cannabinoid based pharmaceutical products throughout Europe, Australia, and North America.
The company announced the divestment of MGC Derma during the December quarter and it will enable the company to focus on becoming a pure bio-pharma company and to capitalize on the growth and expansion of medicinal-cannabis products sector.
The company has appointed key management personnel to support the management and implementation of the Company’s future European and Australian bio-pharma, research and botanical operations. Roby Zomer has been appointed as the Managing Director of the company, with an annual remuneration of $3,00,000 with additional performance shares, based on the share performance and other operational milestones of the company. He will be responsible for the execution of strategy and operations across the entire company. Brett Michell has been appointed as the Executive Chairman of the company, with an annual remuneration $2,40,000 with additional performance shares and he will be responsible for the company’s financing, corporate strategy and development, however, the additional performance shares are subject to the stock performance and other operational milestones of the company.
Moreover, the company has appointed Nativ Segev as the Director and Business Strategy Manager of the company. He has an annual remuneration of $240,000 with additional performance shares which is based on the share performance and other operational milestones of the company. With his vast experience, he will act as a business strategy advisor of the company.
The company has launched an important and unique Research & Development project, CannaHub, with RMIT and the Hebrew University of Jerusalem. This move is to ensure that the company builds a strong foundation of pharmaceutical innovation and can secure a strategic product pipeline for the generation of new industry technologies and applications. The company has launched an educational platform on Cannabis for Epilepsy for providing information on medicinal cannabis and epilepsy.
The Company has completed all architectural plans for the GMP certified Production and Manufacturing facility, after the release of the guidelines on the manufacturing and production of cannabis for medicinal and research purposes, by the Maltese Medical Authority.
Now let us quickly look at the MGC Pharmaceuticals Ltd.’s stock, and the returns it has posted over the last few months. It is trading at a price of $0.043 and increased by 2.381% during the day’s trade, with a market capitalization of $50.94 million. The stock opened at $0.044 which is also the day high of the stock and posted a day low of $0.042. The company has yielded a YTD return of 2.44% posted returns of -34.38%, -41.67% and 7.69% over the last six months, three months and one-month period respectively. It has a 52-week high price of $0.125 and a 52-week low of $0.032, with an average volume of around 2.54 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.